Bristol-Myers Squibb
55.74
0.38 (0.69%)
At close: Jan 14, 2025, 3:59 PM
55.90
0.29%
After-hours Jan 14, 2025, 07:56 PM EST

Bristol-Myers Squibb Revenue Breakdown

Quarter Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017Sep 30, 2017Jun 30, 2017Mar 31, 2017Dec 31, 2016Sep 30, 2016Jun 30, 2016Mar 31, 2016Dec 31, 2015Sep 30, 2015Jun 30, 2015Mar 31, 2015Dec 31, 2014Sep 30, 2014Jun 30, 2014Mar 31, 2014Dec 31, 2013Sep 30, 2013Jun 30, 2013
Abecma Revenue 132.00M 147.00M 125.00M 107.00M 89.00M 67.00M 69.00M 71.00M 24.00M 314.00M 297.00M 342.00M 308.00M 300.00M 2.03B 1.93B 2.04B 1.93B 1.71B 1.58B 1.65B 1.51B 1.36B 1.23B 1.18B 1.10B 948.00M 884.00M 777.00M 734.00M 602.00M 466.00M 437.00M 355.00M 281.00M 216.00M 171.00M 106.00M 134.00M 375.00M 12.00M
Abecma Revenue Growth -10.20% +17.60% +16.82% +20.22% +32.84% -2.90% -2.82% +195.83% -92.36% +5.72% -13.16% +11.04% +2.67% -85.25% +5.50% -5.58% +6.08% +12.90% +8.12% -4.42% +9.56% +10.49% +10.63% +4.76% +6.81% +16.14% +7.24% +13.77% +5.86% +21.93% +29.18% +6.64% +23.10% +26.33% +30.09% +26.32% +61.32% -20.90% -64.27% +3025.00% n/a
Abraxane Revenue 258.00M 239.00M 179.00M 177.00M 241.00M 214.00M 305.00M 266.00M 296.00M 2.89B 2.27B 2.10B 2.16B 2.64B 1.76B 1.82B 1.82B 1.80B 1.80B 1.79B 1.63B 1.51B 1.36B 1.26B 1.20B 1.13B 1.31B 920.00M 840.00M 704.00M 475.00M 305.00M 122.00M 40.00M 5.00M 1.00M 402.00M 363.00M 717.00M 316.00M 352.00M
Abraxane Revenue Growth +7.95% +33.52% +1.13% -26.56% +12.62% -29.84% +14.66% -10.14% -89.74% +27.19% +8.31% -3.14% -18.10% +49.80% -2.97% -0.33% +1.22% -0.17% +0.61% +10.20% +7.68% +11.02% +7.59% +5.86% +6.03% -13.97% +42.39% +9.52% +19.32% +48.21% +55.74% +150.00% +205.00% +700.00% +400.00% -99.75% +10.74% -49.37% +126.90% -10.23% n/a
Breyanzi Revenue 100.00M 71.00M 55.00M 44.00M 39.00M 44.00M 40.00M 30.00M 17.00M 16.00M 15.00M 13.00M 15.00M 12.00M 792.00M 767.00M 778.00M 640.00M 731.00M 675.00M 711.00M 593.00M 662.00M 632.00M 650.00M 535.00M 625.00M 572.00M 593.00M 475.00M 540.00M 484.00M 461.00M 400.00M 443.00M 444.00M 368.00M 342.00M 652.00M 238.00M 312.00M
Breyanzi Revenue Growth +40.85% +29.09% +25.00% +12.82% -11.36% +10.00% +33.33% +76.47% +6.25% +6.67% +15.38% -13.33% +25.00% -98.48% +3.26% -1.41% +21.56% -12.45% +8.30% -5.06% +19.90% -10.42% +4.75% -2.77% +21.50% -14.40% +9.27% -3.54% +24.84% -12.04% +11.57% +4.99% +15.25% -9.71% -0.23% +20.65% +7.60% -47.55% +173.95% -23.72% n/a
Camzyos Revenue 46.00M 29.00M 16.00M 5.00M 3.00M 3.21B 2.67B 2.41B 2.79B 15.00M 14.00M 3.00M 1.65B 1.77B 549.00M 558.00M 544.00M 459.00M 536.00M 491.00M 535.00M 438.00M 527.00M 509.00M 506.00M 463.00M 494.00M 472.00M 451.00M 407.00M 429.00M 411.00M 405.00M 375.00M 398.00M 385.00M 321.00M 271.00M 489.00M n/a 233.00M
Camzyos Revenue Growth +58.62% +81.25% +220.00% +66.67% -99.91% +20.22% +10.69% -13.57% +18513.33% +7.14% +366.67% -99.82% -6.40% +221.68% -1.61% +2.57% +18.52% -14.37% +9.16% -8.22% +22.15% -16.89% +3.54% +0.59% +9.29% -6.28% +4.66% +4.66% +10.81% -5.13% +4.38% +1.48% +8.00% -5.78% +3.38% +19.94% +18.45% -44.58% n/a n/a n/a
Eliquis Revenue 3.20B 3.42B 2.69B 2.65B 3.23B 18.00M 20.00M 22.00M 16.00M 1.72B 1.79B 1.78B 750.00M 714.00M 385.00M 353.00M 367.00M 384.00M 384.00M 382.00M 315.00M 249.00M 269.00M 323.00M 322.00M 330.00M 264.00M 285.00M 241.00M 263.00M 265.00M 240.00M 296.00M 325.00M 366.00M 350.00M n/a n/a n/a n/a n/a
Eliquis Revenue Growth -6.40% +27.34% +1.24% -17.93% +17872.22% -10.00% -9.09% +37.50% -99.07% -4.07% +0.73% +137.33% +5.04% +85.45% +9.07% -3.81% -4.43% 0.00% +0.52% +21.27% +26.51% -7.43% -16.72% +0.31% -2.42% +25.00% -7.37% +18.26% -8.37% -0.75% +10.42% -18.92% -8.92% -11.20% +4.57% n/a n/a n/a n/a n/a n/a
Inrebic Revenue 27.00M 25.00M 23.00M 21.00M 23.00M 23.00M 25.00M 21.00M 12.00M 758.00M 867.00M 826.00M 745.00M 713.00M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Inrebic Revenue Growth +8.00% +8.70% +9.52% -8.70% 0.00% -8.00% +19.05% +75.00% -98.42% -12.57% +4.96% +10.87% +4.49% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Onureg Revenue 44.00M 34.00M 37.00M 32.00M 32.00M 1.92B 1.99B 1.91B 1.91B 773.00M 835.00M 777.00M 55.00M 8.00M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Onureg Revenue Growth +29.41% -8.11% +15.62% 0.00% -98.34% -3.27% +4.36% -0.26% +147.09% -7.43% +7.46% +1312.73% +587.50% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Opdivo Revenue 2.15B 2.20B 2.22B 2.05B 2.06B 6.00M 864.00M 870.00M 814.00M 112.00M 115.00M 96.00M 2.88B 2.92B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Opdivo Revenue Growth -2.59% -0.63% +8.26% -0.78% +34283.33% -99.31% -0.69% +6.88% +626.79% -2.61% +19.79% -96.67% -1.06% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Opdualag Revenue 154.00M 117.00M 104.00M 84.00M 58.00M 792.00M 854.00M 851.00M 854.00M 2.94B 3.28B 3.03B 511.00M 521.00M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Opdualag Revenue Growth +31.62% +12.50% +23.81% +44.83% -92.68% -7.26% +0.35% -0.35% -70.99% -10.24% +8.36% +492.37% -1.92% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Orencia Revenue 927.00M 764.00M 913.00M 883.00M 876.00M 826.00M 151.00M 160.00M 128.00M 470.00M 564.00M 544.00M 369.00M 396.00M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Orencia Revenue Growth +21.34% -16.32% +3.40% +0.80% +6.05% +447.02% -5.62% +25.00% -72.77% -16.67% +3.68% +47.43% -6.82% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Pomalyst/Imnovid Revenue 847.00M 832.00M 877.00M 886.00M 908.00M 156.00M 3.33B 3.35B 3.20B 456.00M 471.00M 446.00M 1.00M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Pomalyst/Imnovid Revenue Growth +1.80% -5.13% -1.02% -2.42% +482.05% -95.31% -0.57% +4.53% +602.19% -3.18% +5.61% +44500.00% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Reblozyl Revenue 234.00M 206.00M 199.00M 190.00M 172.00M 2.80B 555.00M 551.00M 541.00M 18.00M 9.00M 2.00M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Reblozyl Revenue Growth +13.59% +3.52% +4.74% +10.47% -93.85% +403.96% +0.73% +1.85% +2905.56% +100.00% +350.00% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Revlimid Revenue 1.47B 1.75B 2.26B 2.42B 2.50B 483.00M 545.00M 515.00M 510.00M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Revlimid Revenue Growth -16.11% -22.57% -6.61% -3.24% +417.81% -11.38% +5.83% +0.98% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Sotyktu Revenue 25.00M 16.00M 7.00M 1.00M 544.00M 515.00M 48.00M 40.00M 28.00M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Sotyktu Revenue Growth +56.25% +128.57% +600.00% -99.82% +5.63% +972.92% +20.00% +42.86% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Sprycel Revenue 458.00M 429.00M 578.00M 560.00M 525.00M 36.00M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Sprycel Revenue Growth +6.76% -25.78% +3.21% +6.67% +1358.33% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Yervoy Revenue 585.00M 508.00M 568.00M 523.00M 66.00M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Yervoy Revenue Growth +15.16% -10.56% +8.60% +692.42% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Zeposia Revenue 100.00M 78.00M 79.00M 69.00M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Zeposia Revenue Growth +28.21% -1.27% +14.49% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a

Revenue by Geography

Quarter Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017Dec 31, 2016Dec 31, 2015Dec 31, 2014Dec 31, 2013Dec 31, 2010
Europe Revenue 13.50B 10.69B 9.85B 6.27B 5.66B 4.99B 4.21B 3.49B 3.59B 3.93B 3.45B
Europe Revenue Growth +26.29% +8.46% +57.25% +10.75% +13.43% +18.34% +20.74% -2.81% -8.60% +13.98% n/a
Other Region Revenue 834.00M 852.00M 631.00M 524.00M 584.00M 553.00M 528.00M 739.00M 1.11B 842.00M n/a
Other Region Revenue Growth -2.11% +35.02% +20.42% -10.27% +5.61% +4.73% -28.55% -33.54% +32.07% n/a n/a
United States Revenue 31.83B 29.21B 26.58B 15.34B 12.59B 11.36B 10.72B 8.19B 7.72B 8.32B n/a
United States Revenue Growth +8.95% +9.92% +73.23% +21.90% +10.81% +5.95% +30.92% +6.12% -7.24% n/a n/a

Operating Expense Breakdown

Quarter Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017Sep 30, 2017Jun 30, 2017Mar 31, 2017Dec 31, 2016Sep 30, 2016Jun 30, 2016Mar 31, 2016Dec 31, 2015Sep 30, 2015Jun 30, 2015Mar 31, 2015
Selling, General, and Administrative Revenue 1.98B 1.92B 2.37B 2.07B 2.00B 1.93B 1.76B 2.27B 1.93B 1.79B 1.83B 2.35B 1.79B 1.88B 1.67B 2.72B 1.71B 1.63B 1.61B 1.73B 1.05B 1.08B 1.01B 1.34B 1.10B 1.13B 980.00M 1.37B 1.17B 1.20B 1.11B 1.49B 1.16B 1.26B 1.09B 1.55B 1.22B 1.17B 1.06B
Selling, General, and Administrative Revenue Growth +3.17% -18.80% +14.18% +3.49% +3.57% +9.76% -22.24% +17.41% +8.00% -2.40% -22.22% +31.66% -4.99% +12.97% -38.77% +59.50% +4.79% +1.37% -7.38% +64.36% -1.95% +6.96% -24.70% +21.01% -2.39% +15.41% -28.47% +17.19% -2.83% +8.67% -25.50% +27.77% -7.92% +15.87% -29.68% +26.63% +4.53% +10.89% n/a
Research and Development Revenue 2.37B 2.29B 2.69B 2.48B 2.24B 2.26B 2.32B 2.51B 2.42B 2.32B 2.26B 2.52B 3.25B 3.27B 2.23B 3.75B 2.50B 2.52B 2.37B 2.10B 1.38B 1.33B 1.35B 1.38B 1.28B 2.44B 1.25B 1.92B 1.54B 1.66B 1.29B 1.40B 1.14B 1.27B 1.14B 1.92B 1.13B 1.86B 1.02B
Research and Development Revenue Growth +3.44% -14.84% +8.76% +10.53% -0.71% -2.71% -7.53% +3.80% +4.18% +2.70% -10.25% -22.55% -0.61% +47.01% -40.67% +50.06% -0.91% +6.32% +13.11% +51.74% +4.07% -1.70% -2.10% +7.81% -47.43% +94.80% -34.93% +24.50% -6.99% +28.80% -8.00% +23.02% -10.11% +11.44% -40.71% +69.26% -39.01% +82.68% n/a
Sales and Marketing Revenue 1.98B n/a 2.37B 1.40B 2.00B n/a 1.76B 2.27B 1.93B n/a n/a 2.35B 1.79B n/a 1.67B 2.72B 1.71B 1.63B 1.61B 1.73B 1.05B 1.08B 1.01B 1.34B 1.10B 1.13B 980.00M 1.30B 1.15B 1.17B 1.07B 1.46B 1.14B 1.24B 1.07B 1.50B 1.18B 1.14B 1.03B
Sales and Marketing Revenue Growth n/a -100.00% +69.07% -30.10% n/a -100.00% -22.24% +17.41% n/a n/a -100.00% +31.66% n/a -100.00% -38.77% +59.50% +4.79% +1.37% -7.38% +64.36% -1.95% +6.96% -24.70% +21.01% -2.39% +15.41% -24.56% +13.25% -1.71% +8.66% -26.49% +27.71% -7.59% +15.92% -28.85% +27.64% +3.61% +10.30% n/a

Create Price Alert on BMY

Your price alert will notify you when the stock price is above 55.74.

Add to Watchlist